SCHEMBL583958

SCHEMBL583958

CS(=O)(=O)c1ccc(Cc2nc3c(-c4cnc5ccccc5c4)cnn3c(N)c2Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
CHEK1 O14757 6/20 0.40
CCNA2 P20248 6/20 0.40
CDK2 P24941 6/20 0.40
CCNA1 P78396 6/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CYP1A2 P05177 2/20 0.37
GSK3B P49841 2/20 0.36
NTRK1 P04629 1/20 0.36
MET P08581 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
MAP2K2 P36507 1/20 0.36
FLT3 P36888 1/20 0.36
MAPK8 P45983 1/20 0.36
NTRK3 Q16288 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2680114 0.85 CHEK1 (0.39) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10234566 0.84 NTRK1 (0.44) PTGS1PTGS2CHEK1CCNA2CDK2
SCHEMBL588657 0.84 CHEK1 (0.38) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL2679955 0.82 PTGS2 (0.41) PTGS1PTGS2CHEK1CCNA2CDK2
SCHEMBL616205 0.82 PTGS1 (0.34) PTGS1PTGS2CA12CA1CA2
SCHEMBL10235009 0.81 CHEK1 (0.40) CHEK1CCNA2CDK2CCNA1CA12
SCHEMBL10234585 0.80 CHEK1 (0.47) PTGS1PTGS2CHEK1CCNA2CDK2
SCHEMBL6891839 0.79 CHEK1 (0.43) CHEK1CCNA2CDK2CCNA1MET
SCHEMBL10235008 0.79 CHEK1 (0.39) CHEK1CCNA2CDK2CCNA1CA12
SCHEMBL7882770 0.77 CDK2 (0.45) CHEK1CCNA2CDK2CCNA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8591943-B2 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
EP-2417138-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Schering Corporation (US) 2012-02-15 EP disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR PTGS1 1740/4885PTGS2 2688/4885CHEK1 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.